Findings

What do systematic reviews say?

8 questions · 8 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 1 · 12.5%Low 5 · 62.5%Moderate 1 · 12.5%High 0 · 0%

Peginterferon alpha‐2a vs peginterferon alpha‐2b

Discontinuation of medication due to adverse events · people with chronic hepatitis C

Peginterferon alpha‐2a showed no clear difference in adverse events leading to treatment discontinuation Number of events compared with peginterferon alpha‐2b (low certainty).

1 finding from 1 review

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
RR 0.84 [0.57, 1.22]
12 studies · 5340 participants
Low

Peginterferon plus ribavirin vs non‐pegylated interferon plus ribavirin

Discontinuation of medication due to adverse events · people with chronic hepatitis C

Peginterferon plus ribavirin showed no clear difference in adverse events leading to treatment discontinuation compared with non‐pegylated interferon plus ribavirin (low certainty).

1 finding from 1 review

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C 2014 · Cochrane Headline outcomes only
RR 0.86 [0.68, 1.09]
15 studies · 4571 participants
Low

Pegylated (PEG) interferon alpha‐2a vs standard interferon

Treatment discontinuation · patients on HD with HCV infection

Pegylated interferon alpha‐2a showed no clear difference in treatment discontinuation compared with standard interferon (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 0.11 [0.01, 1.96]
1 study · 50 participants
Low

Standard interferon plus ribavirin vs standard interferon

Treatment discontinuation · patients on HD with HCV infection

Standard interferon plus ribavirin may leads to higher treatment discontinuation compared with standard interferon alone (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 2.97 [1.19, 7.36]
1 study · 52 participants
Low

Pegylated interferon plus ribavirin vs pegylated interferon alone

Treatment discontinuation · patients on HD with HCV infection

Pegylated interferon plus ribavirin showed no clear difference in treatment discontinuation compared with pegylated interferon alone (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.71 [0.69, 4.24]
1 study · 377 participants
Low

Standard interferon vs placebo or control

Treatment discontinuation · patients on HD with HCV infection

Standard interferon showed no clear difference in treatment discontinuation compared with placebo or control (moderate certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 4.59 [0.49, 42.69]
4 studies · 116 participants
Moderate

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

Treatment discontinuation · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Injectional interferon alpha‐2B vs Normal saline

Treatment discontinuation · men with chronic (≥ 12 months) Peyronie's disease (single plaque)

It is very uncertain whether injectional interferon alpha‐2B changes discontinuation from treatment compared with saline (very low certainty).

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
RR 0.63 [0.22, 1.76]
1 study · 117 participants
Very low